Desflurane
ApprovedUNKNOWN 0 watching 0 views this week๐ฅ Hot
82
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Aortic Valve Stenosis
Conditions
Aortic Valve Stenosis
Trial Timeline
Jan 1, 2014 โ Dec 1, 2016
NCT ID
NCT02019797About Desflurane
Desflurane is a approved stage product being developed by Baxter for Aortic Valve Stenosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT02019797. Target conditions include Aortic Valve Stenosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02019797 | Approved | UNKNOWN |
Competing Products
20 competing products in Aortic Valve Stenosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban 5 MG + Apixaban 2.5 MG + Warfarin | Artivion | Phase 3 | 72 |
| Edoxaban | Daiichi Sankyo | Phase 3 | 77 |
| NOAC + DAPT | Daiichi Sankyo | Approved | 85 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 52 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| candesartan + placebo | AstraZeneca | Phase 3 | 77 |
| Sugammadex | Merck | Approved | 85 |
| bisoprolol + placebo | Merck | Approved | 85 |
| Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet | Merck | Phase 2/3 | 65 |
| Pelacarsen (TQJ230) 80mg + Matching placebo | Novartis | Phase 2 | 52 |
| fluvastatin | Novartis | Phase 2 | 52 |
| ACZ885 + Placebo | Novartis | Phase 2 | 52 |
| Evolocumab + Placebo | Amgen | Phase 1 | 32 |
| atorvastatin (Lipitor) | Pfizer | Approved | 84 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 76 |
| Ataciguat + Placebo | Sanofi | Phase 1 | 32 |
| Ataciguat (HMR1766) | Sanofi | Phase 2 | 51 |
| Haemocomplettanยฎ P + Saline solution | CSL | Phase 2 | 51 |
| Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Phase 3 | 74 |
| Acetylsalicylic acid + Clopidogrel + Rivaroxaban | Bayer | Phase 3 | 74 |